All In Biotech

Drug Trial Radar · NCT07357610

An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is an open-label, fixed-sequence, two-period Phase 1 clinical trial in healthy adult Chinese participants with a total of 3 cohorts, 16-20 healthy adult Chinese participants are planned to be enrolled in each cohort.

Conditions

  • Healthy Adult Participants

Interventions

  • SIM0270Drug

    oral

  • itraconazoleDrug

    oral

  • RifampinDrug

    oral

  • midazolamDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax) of SIM0270Time frame: Day 1-Day 13, Day 16-Day 30
  2. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of SIM0270Time frame: Day 1-Day 13, Day 16-Day 30
  3. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of SIM0270Time frame: Day 1-Day 13, Day 16-Day 30
  4. Area under concentration-time curve from time 0 to tau (AUC0-tau) of SIM0270Time frame: Day 1-Day 13, Day 16-Day 30
  5. Terminal half-life(t1/2)of SIM0270Time frame: Day 1-Day 13, Day 16-Day 30
  6. Maximum observed concentration (Cmax) of SIM0270Time frame: Day 1-Day 13, Day 20-Day 32
  7. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of SIM0270Time frame: Day 1-Day 13, Day 20-Day 32
  8. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of SIM0270Time frame: Day 1-Day 13, Day 20-Day 32
  9. Terminal half-life(t1/2)of SIM0270Time frame: Day 1-Day 13, Day 20-Day 32
  10. Maximum observed concentration (Cmax) of midazolamTime frame: Day 1-Day 2, Day 11-Day 13
  11. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of MidazolamTime frame: Day 1-Day 2, Day 11-Day 13
  12. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of MidazolamTime frame: Day 1-Day 2, Day 11-Day 13
  13. Terminal half-life(t1/2)of midazolamTime frame: Day 1-Day 2, Day 11-Day 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong University of Qilu Hospital

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.